CD19 and neoplasm: In conclusion, we demonstrate that r/r LBCL patients treated with CD19-directed CAR T-cell therapy with low baseline tumor volume measured using MATV, had a better TTP and OS and a lower incidence of severe CRS compared to high volume patients.